EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

被引：15
|
作者：
Tao, Zhonfei [1 ,2 ,3 ,5 ]
Liu, Bingcheng [1 ,2 ,3 ]
Zhao, Yaozhong [1 ,2 ,3 ]
Wang, Ying [1 ,2 ,3 ]
Zhang, Rongli [1 ,2 ,3 ]
Han, Mingzhe [1 ,2 ,3 ]
Zhang, Li [1 ,2 ,3 ]
Li, Chengwen [2 ,3 ,4 ]
Ru, Kun [2 ,3 ,4 ]
Mi, Yingchang [1 ,2 ,3 ]
Wang, Jianxiang [1 ,2 ,3 ,5 ]
机构：
[1] Chinese Acad Med Sci, Dept Clin Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Hemopathol, Inst Hematol, Tianjin 300020, Peoples R China
[5] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 09期
基金：
中国国家自然科学基金;
关键词：
EUTOS; Chronic myeloid leukemia; Complete cytogenetic response; Overall survival; Progression free survival; Prognosis; PATIENTS RECEIVING IMATINIB; TYROSINE KINASE INHIBITORS; EUROPEAN TREATMENT; PROGNOSTIC SCORE; FOLLOW-UP; CML; FRONTLINE; RECOMMENDATIONS; RESISTANCE; THERAPY;
D O I：
10.1016/j.leukres.2014.06.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Sokal, Euro and newly developed EUTOS scoring systems were validated in 220 Chinese chronic phase chronic myeloid leukemia (CP-CML) patients treated with frontline imatinib. In the EUTOS low-risk and high-risk groups, the 5-year OS was 98.7% vs. 71.4% (P<0.0001), and the 5-year cumulative incidence of complete cytogenetic response (CCyR) was 92.4% vs. 53.8% (p<0.0001). EUTOS score also predicted progression-free survival and duration of CCyR. Low EUTOS index predicted for CCyR. However, Sokal and Euro scores mainly could not discriminate the intermediate-risk from high-risk group in either survival or CCyR. EUTOS score forecasts the prognosis of CP-CML patients treated with first-line imatinib. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1030 / 1035
页数：6
相关论文
共 50 条
  • [41] EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
    Jabbour, Elias
    Cortes, Jorge
    Nazha, Aziz
    O'Brien, Susan
    Quintas-Cardama, Alfonso
    Pierce, Sherry
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2012, 119 (19) : 4524 - 4526
  • [42] Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
    Shanmuganathan, Naranie
    Wadham, Carol
    Shahrin, NurHezrin
    Feng, Jinghua
    Thomson, Daniel
    Wang, Paul
    Saunders, Verity
    Kok, Chung Hoow
    King, Rob M.
    Kenyon, Rosalie R.
    Lin, Ming
    Pagani, Ilaria S.
    Ross, David M.
    Yong, Agnes S. M.
    Grigg, Andrew P.
    Mills, Anthony K.
    Schwarer, Anthony P.
    Braley, Jodi
    Altamura, Haley
    Yeung, David T.
    Scott, Hamish S.
    Schreiber, Andreas W.
    Hughes, Timothy P.
    Branford, Susan
    HAEMATOLOGICA, 2023, 108 (09) : 2380 - 2395
  • [43] Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    Hochhaus, A.
    O'Brien, S. G.
    Guilhot, F.
    Druker, B. J.
    Branford, S.
    Foroni, L.
    Goldman, J. M.
    Mueller, M. C.
    Radich, J. P.
    Rudoltz, M.
    Mone, M.
    Gathmann, I.
    Hughes, T. P.
    Larson, R. A.
    LEUKEMIA, 2009, 23 (06) : 1054 - 1061
  • [44] KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
    Marin, D.
    Gabriel, I. H.
    Ahmad, S.
    Foroni, L.
    de Lavallade, H.
    Clark, R.
    O'Brien, S.
    Sergeant, R.
    Hedgley, C.
    Milojkovic, D.
    Khorashad, J. S.
    Bua, M.
    Alsuliman, A.
    Khoder, A.
    Stringaris, K.
    Cooper, N.
    Davis, J.
    Goldman, J. M.
    Apperley, J. F.
    Rezvani, K.
    LEUKEMIA, 2012, 26 (02) : 296 - 302
  • [45] KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
    D Marin
    I H Gabriel
    S Ahmad
    L Foroni
    H de Lavallade
    R Clark
    S O'Brien
    R Sergeant
    C Hedgley
    D Milojkovic
    J S Khorashad
    M Bua
    A Alsuliman
    A Khoder
    K Stringaris
    N Cooper
    J Davis
    J M Goldman
    J F Apperley
    K Rezvani
    Leukemia, 2012, 26 : 296 - 302
  • [46] Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia
    Nekoohesh, Ladan
    Rostami, Shahrbano
    Nikbakht, Mohsen
    Mohammadi, Saeed
    Babakhani, Davood
    Alimoghaddam, Kamran
    Ghahremani, Mohammad H.
    Chahardouli, Bahram
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01) : E1 - E10
  • [47] ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
    Etienne, Gabriel
    Dulucq, Stephanie
    Lascaux, Axelle
    Schmitt, Anna
    Bidet, Audrey
    Fort, Marie-Pierre
    Lippert, Eric
    Bureau, Caroline
    Adiko, Didier
    Hayette, Sandrine
    Reiffers, Josy
    Nicolini, Franck-Emmanuel
    Mahon, Francois-Xavier
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (01) : 37 - 41
  • [48] Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?
    Zackova, Daniela
    Klamova, Hana
    Dusek, Ladislav
    Muzik, Jan
    Polakova, Katerina Machova
    Moravcova, Jana
    Jurcek, Tomas
    Dvorakova, Dana
    Racil, Zdenek
    Pospisil, Zdenek
    Oltova, Alexandra
    Michalova, Kyra
    Brezinova, Jana
    Razga, Filip
    Doubek, Michael
    Cetkovsky, Petr
    Trneny, Marek
    Mayer, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) : 318 - 321
  • [49] Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
    Gambacorti-Passerini, Carlo
    Antolini, Laura
    Mahon, Francois-Xavier
    Guilhot, Francois
    Deininger, Michael
    Fava, Carmen
    Nagler, Arnon
    Della Casa, Chiara Maria
    Morra, Enrica
    Abruzzese, Elisabetta
    D'Emilio, Anna
    Stagno, Fabio
    le Coutre, Philipp
    Hurtado-Monroy, Rafael
    Santini, Valeria
    Martino, Bruno
    Pane, Fabrizio
    Piccin, Andrea
    Giraldo, Pilar
    Assouline, Sarit
    Durosinmi, Muheez A.
    Leeksma, Onno
    Pogliani, Enrico Maria
    Puttini, Miriam
    Jang, Eunjung
    Reiffers, Josy
    Valsecchi, Maria Grazia
    Kim, Dong-Wook
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07): : 553 - 561
  • [50] Prediction of optimal cytogenetic responses at 6 and 12 months in patients with chronic myeloid leukemia in chronic phase treated with imatinib
    Milosevic, Violeta
    Jovanovic, Maja Perunicic
    Bukumiric, Zoran
    Djordjevic, Vesna
    Jovanovic, Jelica
    Fekete, Marija Dencic
    Lekovic, Danijela
    Bogdanovic, Andrija
    JOURNAL OF BUON, 2021, 26 (03): : 1070 - 1079
12345